Local time

17 06 2019

Lithuania

Bulgaria

Romania

Czech Republic

Slovakia

Poland

Hungary

Croatia

CEE

Hot pharma & economy news

Print -

World pharma news

  • RocheRoche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Polivy™ (polatuzumab vedotin-piiq) in combination with bendamustine plus Rituxan® (rituximab) (BR) for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who have received at least two prior therapies.
    FDA grants Roche's Polivy accelerated approval for people with previously treated aggressive lymphoma
  • Depression is a common and serious problem for older adults. Some 15 to 20 percent of people aged 65 and older who live independently deal with symptoms of major depressive disorder. For residents of nursing homes, the rates of depression may be as high as 50 percent. For some people, medication is an effective part of treatment for depression.
    Weighing risks and benefits of drug treatment for major depression
  • Boehringer IngelheimBoehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced full data from the CAROLINA® trial demonstrating that Trajenta® (linagliptin) did not increase cardiovascular risk compared to glimepiride in adults with type 2 diabetes and cardiovascular risk.(1) The findings were reported today at the American Diabetes Association's 79th Scientific Sessions in San Francisco.
    Full data from CAROLINA® outcome trial support long-term cardiovascular safety profile of Trajenta®
  • SMi Group19 - 20 November 2019, London, UK.
    The global ophthalmic drug market size is expected to reach a value of $30 billion USD by 2023 with growing focus on alternative delivery approaches to replace intravitreal drug delivery and novel drug development being the key factors driving the market.
    Ophthalmic Drugs Conference 2019
  • FDAToday, the U.S. Food and Drug Administration granted accelerated approval to Polivy (polatuzumab vedotin-piiq), in combination with the chemotherapy bendamustine and a rituximab product (a combination known as "BR"), to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies. Polivy is a novel antibody-drug conjugate, and DLBCL is the most common type of non-Hodgkin lymphoma.
    FDA approves first chemoimmunotherapy regimen for patients with relapsed or refractory diffuse large B-cell lymphoma

Pharmaceuticals News & Press Releases

McKinsey Quarterly

Pharma Marketing

Lithuania Economy

Latvia Economy

Estonia Economy

Czech Rep. Economy

Poland Economy

Slovakia Economy

Hungary Economy